Publications by authors named "A Batalla"

Justification and objectives: The Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis and Pediatric Working Groups (PSW and PWG) have developed a set of recommendations for the management of pediatric psoriasis based on the best available evidence and experts' opinion. Methodology: The methodology of nominal groups was followed, with help from a scoping review. A coordinator was designated, and a group of experts was selected based on their experience and knowledge on the management of psoriasis.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted on patients with atopic dermatitis (AD) to explore the impact of atopic comorbidities like asthma and allergic rhinitis on their treatment response.
  • Data was collected from the BIOBADATOP registry, involving 509 patients, mostly adults with severe AD, and analyzed for associations between atopic comorbidities and clinical characteristics.
  • Results indicated that patients with personal atopic comorbidities had more severe symptoms and a higher history of treatments, but no significant differences in treatment response were found after 6 and 12 months, suggesting a need for longer follow-up.
View Article and Find Full Text PDF
Article Synopsis
  • Interest in the therapeutic potential of cannabinoids for mental health is increasing, particularly for conditions like anxiety, depression, and addiction, due to the role of the endocannabinoid system in these disorders.
  • Research has mainly focused on the well-known cannabinoids CBD and Δ9-THC, but there are about 120 lesser-known cannabinoids with varying effects that haven't been thoroughly studied.
  • A systematic review analyzed 22 preclinical studies and one clinical study on minor cannabinoids for various psychiatric conditions, finding that certain cannabinoids like Δ8-THCV, Δ9-THCV, CBDA-ME, and CBDV show promise for conditions ranging from addiction to anxiety and autism spectrum disorders, despite some inconsistencies in the results.
View Article and Find Full Text PDF

Introduction: There is growing recognition of the potential of cannabis to treat various medical conditions and symptoms, such as chronic pain, spasticity, and epilepsy. However, one of the biggest challenges is the assurance of a standardized cannabis product that contains a consistent amount of its main psychoactive substances delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and which is compliant with predetermined specifications for these compounds. This is crucial not only to ensure consistent cannabis quality and dosage for patients but also to effectively translate research findings into clinical practice.

View Article and Find Full Text PDF

Background: In a minority of patients with substance use disorders, there is both unwillingness to treat and serious harm or damage to the patient or society. In these situations, compulsory treatment may be considered. However, it is unclear whether compulsory care is effective in reduction of substance use.

View Article and Find Full Text PDF